Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Q4 2021 Haemonetics Corporation Earnings Conference Call and Webcast. [Operator Instructions] I would now like to hand the conference over to Olga Guyette, Investor Relations. Thank you. Please go ahead.
Olga Guyette
Director, Investor Relations
Thank you. Good morning, everyone. Thank you for joining us for Haemonetics fourth quarter fiscal 21 conference call and webcast. I m joined today by Chris Simon, our CEO; and Bill Burke, our CFO.
This morning, we posted our fourth quarter and fiscal 21 results to our Investor Relations website, along with our fiscal 22 guidance and analytical tables with the information that we ll refer to on this call. Additionally, we provided a complete P&L, balance sheet, summary statement of cash flows, as well as reconciliations of our GAAP to non-GAAP financial results and guidance.
Company s 52-week low was at $63.41
Price action over last quarter: Up 16.87%
Company Profile
Haemonetics Corp sells products used to process, handle, and analyze blood. The firm sells products in four categories: Plasma, Hemostasis Management, Blood Center and Cell Processing. The Plasma business includes plasma collection devices and disposables. Hemostasis Management includes devices and methodologies for measuring coagulation characteristics of blood, Blood Center includes blood collection and processing devices and disposables for red cells and Cell Processing include surgical blood salvage systems, specialized blood cell processing systems, disposables and blood transfusion management software.
Related Articles (HAE)